Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹15,745 Cr
P/E Ratio
52.51
P/B Ratio
10.53
Industry P/E
51.62
Debt to Equity
0.06
ROE
26.38 %
ROCE
33.51 %
Div. Yield
0.11 %
Book Value
1165.94
EPS
187.04
CFO
₹983.33 Cr
EBITDA
₹1,487.96 Cr
Net Profit
₹742.64 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Neuland Lab
| -10.62 | 1.61 | -11.83 | 70.41 | 109.95 | 91.54 | 41.94 |
|
BSE Healthcare
| -5.67 | 2.85 | 2.36 | 19.80 | 20.51 | 22.54 | 10.18 |
|
BSE Mid Cap
| -6.49 | 4.44 | 2.42 | 3.48 | 21.11 | 29.65 | 15.34 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Neuland Lab
| 159.79 | 217.43 | 7.89 | 41.71 | 161.53 | -12.17 | -48.23 |
|
BSE Mid Cap
| 25.84 | 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,068.40 | 13,353.48 | 30.23 | 18.14 | |
| 702.55 | 11,911.87 | 50.74 | 26.54 | |
| 1,550.40 | 16,299.73 | 49.96 | 20.93 | |
| 6,090.00 | 1,62,251.74 | 78.5 | 15.15 |
1 min read•By Research Desk
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics,... cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Read more
Incorporated
1984
Chairman
Davuluri Rama Mohan Rao
Managing Director
Davuluri Saharsh Rao
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Neuland Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Neuland Laboratories Ltd stood at ₹ 1,944 Cr as on 31-Dec-24
The share price of Neuland Laboratories Ltd is ₹12,266.00 (NSE) and ₹12,479.00 (BSE) as of 30-Apr-2025 09:24 IST. Neuland Laboratories Ltd has given a return of 109.95% in the last 3 years.
Neuland Laboratories Ltd has a market capitalisation of ₹ 15,745 Cr as on 29-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Neuland Laboratories Ltd is 10.53 times as on 29-Apr-2025, a 211% premium to its peers’ median range of 3.39 times.
The P/E ratio of Neuland Laboratories Ltd is 52.51 times as on 29-Apr-2025, a 2% premium to its peers’ median range of 51.62 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Neuland Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Neuland Laboratories Ltd.
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. The company's APIs are used in various therapeutic areas, including antiasthmatics, cardiovasculars, antifungal, anticonvulsants, central nervous system, fluoroquinolones, antipsychotic, antibacterial, and anti-parkinson. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
The promoters of Neuland Laboratories Ltd are Davuluri Ownership Trust and DAVULURI SUCHETH RAO. They collectively own 27.99 per cent of the total equity. The chairman of the company is Davuluri Rama Mohan Rao
There is no promoter pledging in Neuland Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
16,625
|
|
|
12,675
|
|
|
12,540
|
|
|
1,59,525
|
| Neuland Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
17.92
|
|
Operating margin(%)
|
20.48
|
|
Net Margin(%)
|
19.32
|
|
Dividend yield(%)
|
0.11
|
Yes, TTM profit after tax of Neuland Laboratories Ltd was ₹300 Cr.
₹-12.00
(
